CLINICAL INPUT RESPONSES

Similar documents
FEP Medical Policy Manual

FEP Medical Policy Manual

Blood Derived Therapies in Refractory Ocular Surface Disease

Amniotic Membrane and Amniotic Fluid

Subject Index. Atopic keratoconjunctivitis (AKC) management 16 overview 15

8/11/2017. Rob Allen, O.D. Rob Allen, Ph.D. Rob Allen, O.D. None. Rob Allen, Ph.D. Represents BioD/BioDOPTIX Amniotic Membrane

Clinical study of sutureless and glue free conjunctival autograft in pterygium surgery

Amniotic membrane transplantation (AMT) without the use of sutures/fibrin glue

Your Ophthalmologist has prescribed you. Poly (carboxymethylglucose sulfate) Medical device. Patient Information

Medical Policy. MP Amniotic Membrane and Amniotic Fluid. Related Policies Experimental / Investigational Services

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Case no.4. Subjective. Subjective (2) Caucasian female, 62 Y.O., consulting for a XXX opinion on her condition.

APPENDIX CLINICAL INPUT RESPONSES

Ophthalmology Times Case Study Yasmin Mali, MD. Case Study

Medical Affairs Policy

Product Insert ProKera is approved by the US FDA (510K Approval) as a class II medical device.

John Rawstron Christchurch 2015

NEW OPPORTUNITIES OF USING THERAPEUTICAL CONTACT LENSES IN OCULAR SURGERY

Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...

rhngf for neurotrophic keratitis first line

Medical Coverage Policy Amniotic Membrane and Amniotic Fluid EFFECTIVE DATE: POLICY LAST UPDATED:

Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary

medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Fitting Keratoconus and Other Complicated Corneas

Ocular and periocular trauma

Scleral Lens Essentials

Amniotic Membrane Transplantation In Ocular Surface Disorders

Learning Objectives. Disclosures 2/2/ BMT Pharmacists Conference Bandage Contact Lens Therapy for Severe Ocular GVHD

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Some of the ophthalmic surgeries

How I Met Your Cornea

Sclerokeratoplasty David S. Chu, M.D. Cases

Differential Diagnosis of Conjunctivitis and Keratoconjunctivitis

Novel therapies for the treatment of persistent corneal epithelial defects

OPHTHALMOLOGIC PEARLS FOR THE NON- OPHTHALMOLOGIST. David G. Gross D.O. Deen-Gross Eye Centers Merrillville-Hobart Deengrosseye.

EYE CARE PROTOCOL FOR PATIENTS IN ITU

BARRY A. SCHECHTER ABSTRACT

INDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.

Aging & Ophthalmology

Innovation In Ophthalmology

Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec

Horizon Laser Vision Center. Post-op Drop and Medication Review. Presented by Dr. Rachael Berger Dr. Courtney Maltman Dr.

a.superficial (adenoid layer).contain lymphoid tissue.

Two Cases of Corneal Ulcer Caused by Ocular Rosacea: Late Versus Prompt Diagnosis and Treatment

Cornea & External Disease research at Moorfields

Dry Eye Prescribing Guidelines

OCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY

Advanced Diagnosis and Management of OSD and Tear Dysfunction

Dry Eye Syndrome (DES)

Lifitegrast Clinical Development Program: Key Findings From 3 Randomized Controlled Trials in Adult Subjects With Dry Eye Disease

Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Optometric Postoperative Cataract Surgery Management

THERAPEUTIC CONTACT LENSES

Ophthalmology. Ophthalmology Services

Implantation of a corneal graft keratoprosthesis for severe corneal opacity in wet blinking eyes

The Tear Film! Cataract Surgery in the Diseased Eye: Ocular Surface Disease

REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE

WARNING LETTER. According to the Indications and Usage section of the FDA approved product labeling (PI):

Disclosures. Disclosures 5/28/18. Amniotic Membrane In the Optometric Practice Workshop. Douglas K. Devries, O.D. Disclosures

Dry Eye Disease Diagnosis and Treatment Pearls from the Trenches (2 hours) Mile Brujic, O.D Kensington Blvd. Bowling Green, OH 43402

Comparison of prognostic value of Roper Hall and Dua classification systems in acute ocular burns

Title: Keeping Step with DEWS2: Clinical Applications Lecturer: Scott G. Hauswirth, OD

Clinical Policy Title: Therapeutic contact lenses

Failure of amniotic membrane transplantation in the treatment of acute ocular burns

Paracentral Corneal Melting in Four Patients With Chronic Graft-Versus-Host Disease

CHEMICAL INJURY IS ONE OF

Various therapies for ocular surface diseases

JMSCR Volume 03 Issue 01 Page January 2015

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES

PAINFUL PAINLESS Contact lens user BOV

Management of acute ulcerative and necrotising herpes simplex and zoster keratitis with amniotic membrane transplantation

CORNEAL CONDITIONS CORNEAL TRANSPLANTATION

What are some common conditions that affect the cornea?

HELP HEAL YOUR PATIENTS DRY EYES.

Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry

Ulcerative Keratitis (Type of Inflammation of the Cornea) Basics

MD (Ophthalmology) May 2007 Examination Paper I MD (Ophthalmology) May 2007 Examination Paper II

Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia

JOURNAL OF OPHTHALMOLOGY AND RELATED SCIENCES

Deep Anterior Lamellar Keratoplasty - Techniques

Interventional procedures guidance Published: 25 September 2013 nice.org.uk/guidance/ipg466

Phone Triage for Optometric Staff ???????? CHEMICAL BURN CHEMICAL BURN

OPHTHALMOLOGY REFERRAL GUIDE FOR GPS

Differential diagnosis of the red eye. Carol Slight Nurse Practitioner Ophthalmology

Therapeutical bandage contact lenses for corneal protection

NCCP Chemotherapy Regimen. Afatinib Therapy

Dry Eye Assessment and Management Study ELIGIBILITY OCULAR EVALUATION FORM

PATIENT COUNSELING. 1

NCCP Chemotherapy Protocol. Afatinib Monotherapy

Corporate Presentation December Two Versatile Platforms Moving Towards Commercialization NASDAQ: EYEG

The Potential For Teleophthalmology in the Patient-Centered Medical Home Model

Specialist Referral Service Willows Information Sheets. Recurrent corneal erosions (indolent ulcers)

PRODUCT INFORMATION ALCAINE. Proparacaine Hydrochloride Sterile Ophthalmic Solution, USP. 5 mg/ml. Topical Anesthetic

Shizuka Koh, M.D. Ph. D.

How to Design a Tobacco Cessation Insurance Benefit

Anatomy: There are 6 muscles that move your eye.

Sample page. Ophthalmology A comprehensive illustrated guide to coding and reimbursement CODING COMPANION

Windows2016 Update What s New in My Specialty? cornea. May 20, 2016 OGDEN SURGICAL-MEDICAL SOCIETY CONFERENCE

To Evaluate the Sociodemographic Factors And Etiology of Corneal Neovascularisation at out Patient Department of M.L.B Medical College, Jhansi.(U.

Transcription:

CLINICAL INPUT RESPONSES Additional Comments With regard to the 9 indications listed above, there was lower range confidence that there is adequate evidence demonstrating that sutureless fixation human amniotic membrane (also called AMG; eg, Prokera, AmbioDisk) performs as well as or better than sutured or glued AMG. Use of AMG would be expected to improve health outcomes and is considered consistent with generally accepted medical practice for: Original Policy Date: April 2015 Page: 1

patients with an epithelial defect that (1) has failed to completely close after 5 days of conservative treatment (2) has failed to demonstrate a decrease in size after 2 days of conservative treatment. Conservative treatment is defined as use of topical lubricants and/or topical antibiotics and/or therapeutic contact lens and/or patching. Failure of multiple modalities should not be required prior to moving to AMG. AMG requires less effort on the part of the patient to adhere to a treatment regimen and has a significant advantage in that regard over treatments that require multiple drops per day. We are in agreement that larger controlled studies are needed to show benefit of AMG in dry eye disease, where the disease is common and such studies should be easy to perform. See Appendices 1 and 2 for details of the clinical input. APPENDI 1: CLINICAL INPUT 2017 Appendix Table 1. Respondent Profile Specialty Society No. Name of Organization Clinical Specialty 1 American Academy of Ophthalmology Ophthalmology Appendix Table 2. Respondent Conflict of Interest Disclosure No. 1. Research support related to the topic where clinical input is being sought Yes/N 2. Positions, paid or unpaid, related to the topic where clinical input is being sought 3. Reportable, more than $1,000, health care related assets or sources of income for myself, my spouse, or my dependent children related to the topic where clinical input is being sought 4. Reportable, more than $350, gifts or travel reimbursements for myself, my spouse, or my dependent children related to the topic where clinical input is being sought Explanation Yes/No Explanation Yes/No Explanation Yes/No Explanation o 1 No No No No Individual physician respondents answered at individual level. Specialty society respondents provided aggregate information that may be relevant to the group of clinicians who provided input to the society-level response. Original Policy Date: April 2015 Page: 2

APPENDI 2: CLINICAL INPUT RESPONSES Objective Clinical input is sought to help determine the appropriate use in clinical practice of amniotic membrane graft (AMG) for ophthalmic disorders. Responses 1. With regard to the use of AMG in each of the following ophthalmic disorders: a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence demonstrating that this use will improve health outcomes. 1 Neurotrophic keratitis 2. With regard to the use of AMG in each of the following ophthalmic disorders: a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that this clinical use is in accordance with generally accepted medical practice. 1 Neurotrophic keratitis Original Policy Date: April 2015 Page: 3

3. With regard to the use of AMG in each of the following ophthalmic disorders: a. Please use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence demonstrating that sutureless fixation AMG (eg, Prokera) performs as well as or better than sutured or glued AMG. 1 Neurotrophic keratitis 4. For individuals with persistent epithelial defects, what objective condition characteristics (ie, patient selection criteria) and management criteria (ie, regarding prior trial of standard treatment options) would describe use of AMG that improves health outcomes and is considered in accordance with generally accepted medical practice? No. Response 1 Patients with an epithelial defect that 1. has failed to completely close after 5 days of conservative treatment 2. has failed to demonstrate a decrease in size after 2 days of conservative treatment Conservative treatment is defined as use of topical lubricants and/or topical antibiotics and/or therapeutic contact lens and/or patching. Failure of multiple modalities should not be required prior to moving to AMG. AMG requires less effort on the part of the patient to adhere to a treatment regimen and has a significant advantage in that Original Policy Date: April 2015 Page: 4

regard over treatments that require multiple drops per day. 5. For individuals with severe dry eye, what objective condition characteristics (ie, patient selection criteria) and management criteria (ie, regarding prior trial of standard treatment options) would describe use of AMG that improves health outcomes and is considered in accordance with generally accepted medical practice? No. Response 1 AMG is a reasonable option when patients demonstrate persistent corneal staining despite conservative therapy. Conservative therapy in this case would include frequent preservative-free tears, hot compresses and efforts to control the environment. At times these may not work because the patient is unable to control the environment or administer drops frequently. Drugs such as cyclosporine or lifitegrast may be helpful in these cases but they may take months to take effect. If the patient's daily activities are significantly affected by dry eye signs and symptoms, AMG may provide rapid relief while waiting for long-term medications to take effect. However, it is unlikely to be of benefit for less-severe disease or disease that responds to conservative therapy. Because it limits acuity it is only viable as a short-term therapy. 6. Additional comments and/or any citations supporting your clinical input on the clinical use of AMG in patients with ophthalmic disorders. No. Additional Comments 1 We are in agreement that larger controlled studies are needed to show benefit of AMG in dry eye disease, where the disease is common and such studies should be easy to perform. It is unlikely that larger RCTs will be possible in less common conditions with multiple different underlying etiologies and severities such as corneal melts or perforations, persistent epithelial defects, or neurotrophic keratitis. The limited clinical literature clearly supports the benefit of AMG in these cases, though sutured AMG is superior to Pro-Kera for the more severe diseases such as perforations and Stevens-Johnson. 7. Is there any evidence missing from the attached draft review of evidence? No. Yes/No Citations of Missing Evidence 1 No Original Policy Date: April 2015 Page: 5